2seventy bio, Inc.
2seventy bio, Inc., headquartered in the United States, is a pioneering biotechnology company focused on developing transformative cell therapies for cancer treatment. Founded in 2020, the company has quickly established itself in the biopharmaceutical industry, particularly in the areas of engineered cell therapies and innovative drug development. With a commitment to advancing the field of oncology, 2seventy bio's core offerings include cutting-edge therapies that harness the power of the immune system to target and eliminate cancer cells. Their unique approach combines scientific expertise with a patient-centric focus, setting them apart in a competitive market. Recognised for its rapid progress and innovative solutions, 2seventy bio is positioned as a leader in the fight against cancer, striving to improve patient outcomes and redefine treatment paradigms.
DitchCarbon Score
How does 2seventy bio, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Health Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
2seventy bio, Inc.'s score of 18 is higher than 52% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
2seventy bio, Inc.'s reported carbon emissions
2seventy bio, Inc., headquartered in the US, currently does not have publicly available carbon emissions data for recent years, nor specific reduction targets or climate commitments outlined in their initiatives. Without concrete figures or defined goals, it is challenging to assess their carbon footprint or climate strategy. However, the absence of emissions data suggests a potential opportunity for the company to establish and communicate its environmental commitments more clearly. As the biotechnology industry increasingly prioritises sustainability, 2seventy bio may benefit from developing measurable targets and transparent reporting to align with industry standards and stakeholder expectations.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
2seventy bio, Inc. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
